Sodium butazolidine cas no:129-18-0
Synonyms: 3,5-Pyrazolidinedione,4-butyl-1,2-diphenyl-, ion(1-), sodium (8CI,9CI);3,5-Pyrazolidinedione,4-butyl-1,2-diphenyl-, sodium deriv. (6CI,7CI);Butazolidine sodium;Diphenyldioxobutylpyrazolidine;GP 26872;Phenylbutazone sodium;Phenylbutazone, sodium salt;Sodium phenylbutazone;
NameSodium butazolidine
CAS129-18-0
Synonyms3,5-Pyrazolidinedione,4-butyl-1,2-diphenyl-, ion(1-), sodium (8CI,9CI);3,5-Pyrazolidinedione,4-butyl-1,2-diphenyl-, sodium deriv. (6CI,7CI);Butazolidine sodium;Diphenyldioxobutylpyrazolidine;GP 26872;Phenylbutazone sodium;Phenylbutazone, sodium salt;Sodium phenylbutazone;
EINECS(EC#)204-935-7
Molecular FormulaC19H20N2NaO2
Molecular Weight330.36
Appearancegray powder complex
Safety
A human poison by ingestion. Human systemic effects by ingestion: respiratory system damage, agranulocytosis, and dermatitis. An experimental poison via subcutaneous, intravenous, and intraperitoneal routes. An anti-inflammatory drug. When heated to decomposition it emits toxic fumes of NOx and Na2O.
Organism |
Test Type |
Route |
Reported Dose (Normalized Dose) |
Effect |
Source |
mouse |
LD50 |
intraperitoneal |
169mg/kg (169mg/kg) |
|
Research Progress in Organic-Biological and Medicinal Chemistry. Vol. 2, Pg. 314, 1970. |
mouse |
LD50 |
intravenous |
94mg/kg (94mg/kg) |
|
Farmaco, Edizione Scientifica. Vol. 13, Pg. 922, 1958. |
mouse |
LD50 |
oral |
476mg/kg (476mg/kg) |
|
Research Progress in Organic-Biological and Medicinal Chemistry. Vol. 2, Pg. 314, 1970. |
mouse |
LD50 |
subcutaneous |
257mg/kg (257mg/kg) |
|
Nippon Yakurigaku Zasshi. Japanese Journal of Pharmacology. Vol. 63, Pg. 43, 1967. |
rabbit |
LD50 |
intravenous |
146mg/kg (146mg/kg) |
|
Schweizerische Medizinische Wochenschrift. Vol. 84, Pg. 1315, 1954. |
rat |
LD50 |
intravenous |
113mg/kg (113mg/kg) |
|
Farmaco, Edizione Scientifica. Vol. 13, Pg. 922, 1958. |
rat |
LD50 |
oral |
855mg/kg (855mg/kg) |
|
Indian Journal of Physiology and Pharmacology. Vol. 5, Pg. 113, 1961. |
rat |
LD50 |
subcutaneous |
310mg/kg (310mg/kg) |
BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) |
Arzneimittel-Forschung. Drug Research. Vol. 8, Pg. 229, 1958. |
women |
LDLo |
oral |
16mg/kg/D (16mg/kg) |
LUNGS, THORAX, OR RESPIRATION: STRUCTURAL OR FUNCTIONAL CHANGE IN TRACHEA OR BRONCHI
BLOOD: AGRANULOCYTOSIS
SKIN AND APPENDAGES (SKIN): "DERMATITIS, OTHER: AFTER SYSTEMIC EXPOSURE" |
Annals of Internal Medicine. Vol. 39, Pg. 1096, 1953. |